Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 6 | 3 |
| 2 Introduction | 9 | 20 |
| 2.1 Therapy Area Introduction | 9 | 1 |
| 2.1.1 Glaucoma | 9 | 1 |
| 2.1.2 63TAge-Related Macular Degeneration | 9 | 1 |
| 2.1.3 Diabetic Macular Edema | 10 | 1 |
| 2.1.4 Diabetic Retinopathy | 10 | 1 |
| 2.1.5 Dry Eye Syndrome | 10 | 1 |
| 2.2 Symptoms | 11 | 2 |
| 2.3 Etiology and Pathophysiology | 13 | 1 |
| 2.3.1 Etiology | 13 | 2 |
| 2.3.2 Pathophysiology | 15 | 1 |
| 2.3.2.1 Glaucoma | 15 | 1 |
| 2.3.2.2 Age-Related Macular Degeneration | 15 | 1 |
| 2.3.2.3 Diabetic Macular Edema | 16 | 1 |
| 2.3.2.4 Diabetic Retinopathy | 17 | 1 |
| 2.3.2.5 Dry Eye Syndrome | 17 | 1 |
| 2.4 Co-morbidities and Complications | 18 | 1 |
| 2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates | 19 | 1 |
| 2.5.1 Glaucoma | 20 | 1 |
| 2.5.2 Age-Related Macular Degeneration | 21 | 1 |
| 2.5.3 Diabetic Macular Edema | 22 | 1 |
| 2.5.4 Diabetic Retinopathy | 22 | 2 |
| 2.5.5 Dry Eye Syndrome | 24 | 2 |
| 2.6 Treatment | 26 | 3 |
| 3 Key Marketed Products | 29 | 9 |
| 3.1 Overview | 29 | 1 |
| 3.2 Lucentis (ranibizumab) | 29 | 1 |
| 3.3 Eylea (aflibercept) | 30 | 1 |
| 3.4 Avastin (bevacizumab) | 31 | 1 |
| 3.5 Restasis (cyclosporine) | 32 | 2 |
| 3.6 Alphagan (brimonidine tartrate) | 34 | 1 |
| 3.7 Lumigan (bimatoprost) | 35 | 1 |
| 3.8 Xalatan (latanoprost) | 36 | 2 |
| 4 Pipeline Landscape Assessment | 38 | 23 |
| 4.1 Overview | 38 | 1 |
| 4.2 Pipeline Development Landscape | 38 | 3 |
| 4.3 Mechanisms of Action in the Pipeline | 41 | 3 |
| 4.4 Clinical Trials | 44 | 1 |
| 4.4.1 Failure Rate | 44 | 1 |
| 4.4.1.1 Indication | 45 | 1 |
| 4.4.1.2 Molecule Type | 46 | 1 |
| 4.4.1.3 Mechanism of Action | 47 | 1 |
| 4.4.2 Clinical Trial Duration | 48 | 1 |
| 4.4.2.1 Indication | 49 | 1 |
| 4.4.2.2 Molecule Type | 50 | 1 |
| 4.4.2.3 Mechanism of Action | 51 | 1 |
| 4.4.3 Clinical Trial Size | 52 | 1 |
| 4.4.3.1 Indication | 53 | 1 |
| 4.4.3.2 Molecule Type | 54 | 1 |
| 4.4.3.3 Mechanism of Action | 55 | 1 |
| 4.4.4 Aggregate Clinical Program Size | 56 | 1 |
| 4.4.4.1 Indication | 57 | 1 |
| 4.4.4.2 Molecule Type | 58 | 1 |
| 4.4.4.3 Mechanism of Action | 59 | 1 |
| 4.4.5 Conclusion | 60 | 1 |
| 5 Multi-Scenario Market Forecast to 2022 | 61 | 11 |
| 5.1 Overall Market Size | 61 | 1 |
| 5.2 Generic Penetration | 62 | 1 |
| 5.3 Revenue Forecast by Molecular Target | 63 | 1 |
| 5.3.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) | 63 | 1 |
| 5.3.2 Antihistamines (H1 Receptor) | 64 | 1 |
| 5.3.3 Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) | 65 | 1 |
| 5.3.4 IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway) | 66 | 1 |
| 5.3.5 Assessment of Key Pipeline Products | 66 | 1 |
| 5.3.5.1 Fovista Ophthotech | 66 | 1 |
| 5.3.5.2 Drug Forecast | 67 | 1 |
| 5.3.5.3 SPK-RPE65 Spark Therapeutics | 67 | 1 |
| 5.3.5.4 Drug Forecast | 67 | 1 |
| 5.3.5.5 Lampalizumab Roche | 68 | 1 |
| 5.3.5.6 Drug Forecast | 69 | 1 |
| 5.3.5.7 Rhopressa Aerie Pharmaceuticals | 69 | 1 |
| 5.3.5.8 Drug Forecast | 69 | 1 |
| 5.3.5.9 Roclatan Aerie Pharmaceuticals | 70 | 1 |
| 5.3.5.10 Drug Forecast | 71 | 1 |
| 6 Company Analysis and Positioning | 72 | 17 |
| 6.1 Revenue and Market Share Analysis by Company | 73 | 5 |
| 6.1.1 Novartis Will Pipeline Product Approvals Offset the Patent Expiry of Lucentis? | 78 | 1 |
| 6.1.2 Bayer Growing Revenues for Eylea Set to Increase Bayer s Revenue | 79 | 1 |
| 6.1.3 Regeneron Growing Revenues for Eylea Will Make it the Top Selling Ophthalmology Drug | 80 | 1 |
| 6.1.4 Roche Gradual Decline in Revenues Due to Lucentis Patent Expiries and Uptake of Generics | 81 | 1 |
| 6.1.5 Ophthotech Pipeline Product Approval will Result in Blockbuster Status Within the Forecast Period | 82 | 1 |
| 6.1.6 Spark Therapeutics Pipeline Product Approval to Resulting in Large Revenues in a Short Space of Time | 83 | 1 |
| 6.1.7 Santen Patent Expiration of Eylea to Cause Gradual Decline in Revenue | 83 | 2 |
| 6.2 Company Landscape | 85 | 1 |
| 6.3 Marketed and Pipeline Portfolio Analysis | 86 | 3 |
| 7 Strategic Consolidations | 89 | 11 |
| 7.1 Licensing Deals | 89 | 1 |
| 7.1.1 Deals by Region, Year and Value | 89 | 2 |
| 7.1.2 Deals by Stage of Development and Value | 91 | 1 |
| 7.1.3 Deals by Molecule Type, Mechanism of Action and Value | 92 | 2 |
| 7.1.4 Table for Licensing Deals Valued Above $100m | 94 | 1 |
| 7.2 Co-development Deals | 95 | 1 |
| 7.2.1 Deals by Region, Year and Value | 95 | 2 |
| 7.2.2 Deals by Stage of Development and Value | 97 | 1 |
| 7.2.3 Deals by Molecule Type, Mechanism of Action and Value | 98 | 1 |
| 7.2.4 Table for Co-development Deals Valued Above $100m | 99 | 1 |
| 8 Appendix | 100 | 51 |
| 8.1 References | 100 | 8 |
| 8.2 Table of All Clinical Stage Pipeline Products | 108 | 39 |
| 8.3 Abbreviations | 147 | 1 |
| 8.4 Disease List | 147 | 1 |
| 8.5 Methodology | 148 | 2 |
| 8.5.1 Coverage | 148 | 1 |
| 8.5.2 Secondary Research | 148 | 1 |
| 8.5.3 Market Size and Revenue Forecasts | 148 | 1 |
| 8.5.4 Pipeline Analysis | 149 | 1 |
| 8.5.5 Competitive Landscape | 149 | 1 |
| 8.6 Contact Us | 150 | 1 |
| 8.7 Disclaimer | 150 | 1 |